SCHEMBL3663503

SCHEMBL3663503

NC(=O)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
FBP1 P09467 1/20 0.51
PTGES2 Q9H7Z7 1/20 0.48
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HTT P42858 2/20 0.47
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
F2 P00734 1/20 0.46
PSEN1 P49768 4/20 0.45
PSEN2 P49810 4/20 0.45
APH1B Q8WW43 4/20 0.45
NCSTN Q92542 4/20 0.45
APH1A Q96BI3 4/20 0.45
PSENEN Q9NZ42 4/20 0.45
MEN1 O00255 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933822 0.86 FBP1 (0.49) MAPTFBP1PTGES2KMT2AALDH1A1
SCHEMBL194745 0.84 MAPT (0.53) MAPTFBP1PTGES2KMT2AALDH1A1
SCHEMBL682128 0.82 MAPT (0.63) MAPTFBP1KMT2AALDH1A1HTT
SCHEMBL3933827 0.81 FBP1 (0.48) MAPTFBP1PTGES2KMT2AALDH1A1
SCHEMBL19341771 0.78 MAPT (0.51) MAPTFBP1KMT2AALDH1A1HTT
SCHEMBL8230214 0.77 KMT2A (0.53) MAPTFBP1PTGES2KMT2AALDH1A1
SCHEMBL4207122 0.77 KMT2A (0.53) MAPTPTGES2KMT2AALDH1A1HTT
SCHEMBL6804437 0.77 HTR6 (0.55) MAPTFBP1PTGES2KMT2AALDH1A1
SCHEMBL24254279 0.77 KMT2A (0.56) MAPTPTGES2KMT2AALDH1A1HTT
SCHEMBL265540 0.76 FBP1 (0.52) MAPTFBP1KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101300013-B [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto PORTOLA PHARM INC 2012-11-28 CN disclosed
EP-2146705-A2 COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR Portola Pharmaceuticals, Inc. (US) 2010-01-27 EP disclosed
WO-2008137787-A2 COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR PORTOLA PHARMACEUTICALS, INC. (US) 2008-11-13 WO disclosed
CN-101300013-A [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto PORTOLA PHARM INC (US) 2008-11-05 CN disclosed
EP-1412364-A1 PLATELET ADP RECEPTOR INHIBITORS Portola Pharmaceuticals, Inc. (US) 2004-04-28 EP disclosed
WO-2003011872-A1 PLATELET ADP RECEPTOR INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-02-13 WO disclosed